caa a22 4500 606241302 CHVBK 20210128101312.0 cr unu---uuuuu 210128e20150501xx s 000 0 eng 10.1007/s00508-014-0674-6 doi (NATIONALLICENCE)springer-10.1007/s00508-014-0674-6 Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance [Elektronische Daten] [Sonja A. Selemetjev, Svetlana B. Savin, Ivan R. Paunovic, Svetislav B. Tatic, Dubravka Cvejic] Änderungen im Expressionsmuster von apoptotischen Molekülen (Galectin-3, Bcl-2, Bax, Survivin) im Rahmen der Progression der Malignität von Schilddrüsentumoren und deren klinische Bedeutung Summary: Background: Papillary carcinoma of the thyroid (PTC) is generally a slow growing tumor with favorable prognosis, while anaplastic thyroid carcinoma (ATC) is highly aggressive malignancy. Genetic defects in apoptotic pathways may contribute to differences in their biological behavior. Methods: In this study, we analyzed immunohistochemically the expression of apoptosis-related molecules: galectin-3, Bcl-2, survivin (antiapoptotic), and Bax (pro-apoptotic), in archival tissue sections of PTC (n = 69) and ATC (n = 30) and correlated the results with clinicopathological parameters of these tumors. Results: Galectin-3 and Bcl-2 showed a similar trend of down-regulation from high levels of both in PTC to low levels in ATC (p < 0.05). Bax was expressed at high levels in both type of thyroid carcinoma. Expression of survivin increased from PTC to ATC (p < 0.05), which may, at least in part, further facilitate the ability of malignant thyroid cell of ATC to escape programmed cell death despite high Bax expression. Only survivin, but not galectin-3, Bcl-2, or Bax, correlated significantly with lymph node metastasis presence and advanced stages of malignancy. Conclusions: In conclusion, this study documented down-regulation of galectin-3 and Bcl-2 (antiapoptotic molecules) and stepwise increase of survivin (inhibitor of apoptosis), during thyroid tumor progression from PTC to ATC. Correlation of high survivin expression with aggressive behavior implies its role in progression of thyroid tumor malignancy and suggests that survivin could be a useful tool in the prediction of aggressiveness of a subset of papillary carcinomas and a possible target for molecular therapy for ATC patients. Springer-Verlag Wien, 2014 Thyroid malignancy progression nationallicence Galectin-3 nationallicence Bcl-2 nationallicence Bax nationallicence Survivin nationallicence Progression der Malignität von Schilddrüsentumoren nationallicence Galektin-3 nationallicence Selemetjev Sonja A. Institute for the Application of Nuclear Energy—INEP, University of Belgrade, Banatska 31b, 11080, Zemun—Belgrade, Serbia aut Savin Svetlana B. Institute for the Application of Nuclear Energy—INEP, University of Belgrade, Banatska 31b, 11080, Zemun—Belgrade, Serbia aut Paunovic Ivan R. Center for Endocrine Surgery, Institute for Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, Belgrade, Serbia aut Tatic Svetislav B. Institute of Pathology, Medical Faculty, University of Belgrade, Belgrade, Serbia aut Cvejic Dubravka Institute for the Application of Nuclear Energy—INEP, University of Belgrade, Banatska 31b, 11080, Zemun—Belgrade, Serbia aut Wiener klinische Wochenschrift Springer Vienna 127/9-10(2015-05-01), 337-344 0043-5325 127:9-10<337 2015 127 508 https://doi.org/10.1007/s00508-014-0674-6 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-014-0674-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Selemetjev Sonja A. Institute for the Application of Nuclear Energy—INEP, University of Belgrade, Banatska 31b, 11080, Zemun—Belgrade, Serbia aut NATIONALLICENCE 700 1- Savin Svetlana B. Institute for the Application of Nuclear Energy—INEP, University of Belgrade, Banatska 31b, 11080, Zemun—Belgrade, Serbia aut NATIONALLICENCE 700 1- Paunovic Ivan R. Center for Endocrine Surgery, Institute for Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, Belgrade, Serbia aut NATIONALLICENCE 700 1- Tatic Svetislav B. Institute of Pathology, Medical Faculty, University of Belgrade, Belgrade, Serbia aut NATIONALLICENCE 700 1- Cvejic Dubravka Institute for the Application of Nuclear Energy—INEP, University of Belgrade, Banatska 31b, 11080, Zemun—Belgrade, Serbia aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/9-10(2015-05-01), 337-344 0043-5325 127:9-10<337 2015 127 508